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cell response (De Magistris et al., 1992; Racioppi et al.,
1993; Jameson and Bevan, 1995; Dittel et al., 1997).Summary
Despite a failure to stimulate any measurable functional
responses, pure antagonists do elicit a modified signal-Inhibition of T cell activation can be mediated by ana-
ing response characterized by generation of p21z withlogs of the original antigenic peptide (TCR antago-
little or no p23z, together with the recruitment of ZAP-nists). Here, a T cell clone expressing two distinct
70 without the phosphorylation or enzymatic activationTCR was used to investigate whether such inhibition
of the bound ZAP-70 (Madrenas et al., 1995; Reis einvolves an active mechanism by examining whether
Sousa et al., 1996; La Face et al., 1997; Hemmer et al.,an antagonist for one TCR could influence responses
1998).stimulated by the other TCR engaging its agonist. Our
Various mechanisms have been proposed to explainresults demonstrate functional cross-inhibition under
the function of antagonist ligands. Among these arethese conditions involving the ability of antagonist:
inhibition of a TCR conformational change (Janeway,TCR interactions to diminish Lck enzymatic activity
1995), sterile binding to TCR resulting in a competitiveassociated with the agonist-recognizing second TCR,
reduction in occupancy by agonist (De Magistris et al.,apparently through enhancement of SHP-1 associa-
1992; Daniels et al., 1999; Stotz et al., 1999) or in interfer-tion with these receptors. Our findings reveal that inhi-
ence with serial engagement (Valitutti et al., 1995; Violabition of cellular responses by antagonists arises at
et al., 1997), consumption or sequestration of limitingleast in part from active negative regulation of proxi-
signaling molecules in ineffective complexes (Torigoemal TCR signaling and identify elements of the bio-
et al., 1998), and a disruption of effective TCR orchemical process.
TCR:coreceptor oligomerization (Jameson and Bevan,
1995; Madrenas et al., 1997; Reich et al., 1997; Boniface
Introduction et al., 1998). Recently, attention has been focused on
observations of the low affinity of some antagonists
Engagement of the TCR with peptide/MHC complexes for the TCR, especially an increased dissociation rate
elicits biochemical intracellular signaling cascades that compared to effective agonists (Alam et al., 1996; Lyons
activate specific genes required for T cell proliferation, et al., 1996; Rabinowitz et al., 1996; Kersh et al., 1998).
differentiation to effector function, and generation of This rapid dissociation has been proposed to result in
memory cells (Crabtree and Clipstone, 1994; Weiss and partial signaling by early cessation of TCR engagement,
Littman, 1994). A key early signaling event triggered by disrupting the kinetics of signal development through
potent ligands is the activation of the src family kinase the TCR (McKeithan, 1995). Although appealing, this
Lck, leading to tyrosine phosphorylation of the CD3 hypothesis does not account for one report of increased
components e and z (Straus and Weiss, 1992; Thome et affinity of an antagonist versus an agonist ligand mea-
al., 1995). With highly stimulatory ligands, the ratio of sured using live cells (Sykulev et al., 1998).
partially tyrosine phosphorylated z (p21 monomers in Some of these hypotheses predict that for cells with
mouse, p32 dimers in human) to fully phosphorylated z two TCR of distinct peptide/MHC molecule specificity,
(p23 monomers in mouse, p38 dimers in human) ap- inhibition of responses to a stimulatory ligand for one
proaches 1:1 (Sloan-Lancaster et al., 1994; Madrenas receptor would not be seen using an antagonist for the
et al., 1995; Reis e Sousa et al., 1996; La Face et al., other TCR. The present study utilized a T cell clone
1997; Hemmer et al., 1998; Kersh et al., 1998). Phosphor- expressing two distinct TCR to look for functional and
ylation of the ITAM in these TCR-associated proteins is biochemical cross-talk between the TCR upon exposure
followed by SH2-domain±dependent binding of ZAP-70, to agonist-antagonist combinations. Exposure of this
which in the case of TCR containing fully phosphorylated dual TCR clone to the agonist of one TCR and an antago-
nist for the other led to reductions in cellular responses
and kinase activity of the TCR interacting with agonist,³ To whom correspondence should be addressed (e-mail: bonnie.
dittel@yale.edu). despite the presence of increased Lck protein in these
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Figure 1. Dose-Dependent Peptide Antago-
nism of MBP TCR-Expressing Clones
(A and B) B10.PL splenocytes were prepulsed
with K4M at 0.1 mg/ml for 2 hr at 378C before
coculture with clone 19 in the presence or
absence of Q3A ([A], closed circle), Q3AK4A
([A], open circle), Q3AK4M ([A], closed square),
R5L ([B], closed circle), K4AR5L ([B], open
circle), or K4MR5L ([B], closed square) used
at 1.2 to 100 mM. The prepulse level corre-
sponds to proliferation of clone 19 in re-
sponse to K4M prepulsed splenocytes in the
absence of exogenously added peptide.
(C) The MBP 31 clone was cocultured with
B10.PL (I-Au) splenocytes in the presence of 1:10 dilutions of Ac1-11 (closed circle), K4A (open circle), or K4M (closed square) from 0.001 to
10 mM. Proliferation was measured by [3H]TdR incorporation and presented as CPM.
receptors. This decrease in kinase activity was associ- predicted increased affinities of K4A and K4M for I-Au
were evident in biological assays. Using a MBP TCR-ated with enhanced levels of the tyrosine phosphatase
expressing clone, T cell proliferation in response to theSHP-1 in the TCR complexes. These data indicate that
Ac1-11 peptide was first detected at 0.1 mM, whereasan active negative regulatory process contributes to the
the sensitivity was increased to 0.01 and 0.001 mM withinhibition mediated by TCR antagonists and defines sev-
the K4A and K4M peptides, respectively (Figure 1C).eral of the key underlying events.
Consistent with these proliferation data, the Q3AK4A
and K4AR5L peptides were more potent in antagonizingResults
responses dependent on this TCR than the Q3A and
R5L peptides, though they were similar to each other inCharacterization of Antagonists for the D10
activity (Figures 1A and 1B), whereas the Q3AK4M (Fig-and MBP TCR
ure 1A) and K4MR5L (Figure 1B) peptides generatedWe have previously described the generation of CD4 T
the best antagonists for the MBP TCR. The expectedcell clones from the spleen of a tg mouse expressing the
specificity of action of the agonist and antagonist li-rearranged TCR a and b chain genes from the D10.G4.1
gands of the MBP TCR was seen with cells bearing theclone (D10) (Dittel et al., 1997) specific for hen egg conal-
D10 TCR by a lack of proliferation or antagonism inbumin (CA) residues 134±146 (CA134-146) presented by
response to the Ac1-11, Q3A, Q3AK4A, Q3AK4M, R5L,the MHC class II molecule I-Ak (Kaye et al., 1983). In
K4AR5L, and K4MR5L peptides presented by I-Ak or I-Auaddition, we have previously characterized an antago-
APC (data not shown). The reciprocal specificity wasnist peptide for the D10 TCR (E8A) in which the E at
confirmed for the MBP TCR by lack of proliferation orposition eight of the peptide is substituted with A (Dittel
antagonism in response to the CA134-146 or E8A pep-
et al., 1997) with the capacity to inhibit/antagonize both
tides presented by I-Ak or I-Au APC (data not shown).
cell proliferation and cytokine secretion from Th1, Th2,
and Th0 D10 TCR clones (Dittel et al., 1997). Characterization of a Dual TCR Clone Expressing
To extend these studies to an examination of the Both the D10 and MBP TCR
mechanism of TCR antagonism, we searched for antag- Having characterized two distinct TCR for their agonist
onists of a TCR that recognizes the acetylated N-termi- and antagonist ligands, it was possible to design an
nal peptide of myelin basic protein (MBP) (Ac1-11) approach to investigate whether antagonists' function
bound to I-Au (Baron et al., 1993). For this purpose, we may involve mechanisms other than interference with
isolated T cell clones from the spleen of a tg mouse agonist-TCR engagement. CD4 T cell clones were gen-
expressing the rearranged TCR a and b chains of an erated from a mouse that expressed both transgenes
MBP-specific CD4 T cell clone (Hardardottir et al., 1995) and was heterozygous at the MHC (H-2kxu). The clones
and screened Ac1-11 peptides containing single amino stably expressed both TCR, as assessed by staining
acid substitutions in the TCR binding residues for gener- with the 3D3 (Kaye et al., 1983) and 19G (Baron et al.,
ation of antagonist activity, as we have previously de- 1993) clonotypic mAbs, which are specific for the D10
scribed for the D10 TCR (Dittel et al., 1997). Weak and TCR and MBP TCR, respectively (Figure 2A). Because
variably active antagonist ligands were formed using TCR chains can cross-pair, although with distinct effi-
peptides with A substituted at position 3 for the wild- ciencies (Saito et al., 1989; Couez et al., 1991), the speci-
type Q (Q3A) or L substituted at position 5 for R (R5L) ficity of the dual receptor D10/MBP 5-3 clone used in
(Figures 1A and 1B). In an effort to obtain more active this study was analyzed using T cell proliferation and
inhibitors, we attempted to increase the affinity of the the CA134-146, Ac1-11, K4A, and K4M peptides. The
antagonist peptides for the I-Au MHC class II molecule D10/MBP 5-3 clone proliferates in response to the
by substituting K at position four of Ac1-11 with A (K4A) CA134-146 peptide in a dose-dependent manner when
or M (K4M) in the Q3A and R5L antagonist peptides. It presented by I-Ak or I-Akxu APC but not when this peptide
has been reported that the K4A substitution increases is offered together with I-Au APC (Figure 2B). Similarly,
the affinity of Ac1-11 for the I-Au MHC class II molecule the D10/MBP 5-3 clone proliferates in a dose-dependent
more than 40-fold (Fugger et al., 1996), and the K4M manner to the Ac1-11 peptide when presented by I-Au
peptide binds I-Au even more avidly (Fairchild et al., or I-Akxu APC but not when it is offered together with
I-Ak APC (Figure 2B). To confirm that possible heterodimer1993). Consistent with previously published results, the
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Figure 2. TCR Expression by and Response
Characteristics of Single and Dual TCR
Clones
(A) TCR expression of the D10 and MBP TCR
on T cell clones obtained from D10, MBP, and
D10/MBP TCR tg mice. The D10 Th2.3, clone
19, and D10/MBP 5-3 clones were stained for
the expression of the D10 and MBP TCR us-
ing the TCR clonotypic mAbs 3D3 and 19G,
respectively. Histograms represent fluores-
cence intensity on the horizontal axis and rel-
ative cell number on the vertical axis. The
horizontal bar in each histogram defines
background staining.
(B) The D10/MBP 5-3 clone was cocultured
with B10.BR (I-Ak) (left panel), B10.PL (I-Au)
(center panel), or with (B10.BR/B10.PL)F1
(I-Akxu) (right panel) splenocytes in the presence
of Ac1-11 (closed circle), K4A (square), K4M
(triangle), or CA134-146 (open circle) offered
at 0.001 to 10 mM.
(C) The D10/MBP 5-3 clone was cocultured
with B10.PL splenocytes and 0.5 mg/ml Ac1-
11 (open circles) or B10.BR splenocytes and
0.05 mg/ml CA134-146 (closed circles) in the
presence of serial dilutions of 19G ascites
(left panel) or purified 3D3 (right panel). Anti-
Fc receptor mAb (10 mg/ml) was also added
to each well. Proliferation was measured as
for Figure 1.
formation between the TCR chains of the D10 and MBP responds to CA134-146 similarly to D10 single TCR
clones (Dittel et al., 1997).TCR have no functional activity, we performed mAb inhi-
bition studies using 3D3 and 19G. As shown in Figure Figure 3A shows that the proliferative response of the
D10/MBP 5-3 clone is inhibited by the E8A antagonist2C, proliferation of the D10/MBP 5-3 clone stimulated
with I-Au APC presenting Ac1-11 was specifically inhib- upon stimulation with CA134-146, as reported for D10
clones (Dittel et al., 1997). Likewise, the response ofited with the 19G mAb but not 3D3. The reciprocal ex-
periment gave a similar result with the 3D3 mAb but the D10/MBP 5-3 clone is inhibited by the Q3AK4M
antagonist upon stimulation with the K4A agonist (Figurenot 19G specifically inhibiting proliferation induced by
CA134-146 presented by I-Ak APC. Thus, as expected 3D), similar to the single TCR MBP clone shown in Figure
1. Thus, both the D10 and MBP TCR in the D10/MBP 5-3from the original T hybridoma fusion studies (Kappler
et al., 1981), mixed peptide/MHC specificities are not clone are fully functional and show the same behavior
upon exposure to the previously characterized agonistseen using this dual TCR clone.
To further investigate the fine specificity of this dual and antagonist ligands as single TCR clones. The W7M
and the HEL30-53 peptides are used as controls forTCR D10/MBP clone, we measured proliferation to the
Ac1-11 analog peptides K4A and K4M. As with the MBP binding to I-Ak and I-Au, respectively, and have no intrin-
sic ability to stimulate either the D10 or MBP TCR.TCR clone shown in Figure 1B, proliferation to K4A and
K4M was first detected at lower peptide concentrations
than with Ac1-11 (Figure 2B). The sensitivity of the D10/ Antagonism Can Be Observed Using TCR-Engaging
Ligands Involving Distinct MHC MoleculesMBP-dual TCR clone to Ac1-11, K4A, and K4M was
reduced by approximately 10-fold when I-Akxu APC were This dual D10/MBP 5-3 T cell clone was then used to
examine whether agonist stimulation through the D10used (Figure 2B). These data show that the D10/MBP
5-3 dual TCR clone responds to Ac1-11, K4A, and K4M TCR could be inhibited by antagonist engagement of
the MBP TCR. Functional cross-antagonism betweenin a similar manner as the MBP single TCR clone shown
in Figure 1C. Likewise, the D10/MBP 5-3 clone also two different TCR is demonstrated in Figure 3B by the
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Q3AK4M mediated antagonism (Figure 4E). These data
demonstrate that both ligands must be presented on
the same APC in order to observe inhibition of responses
mediated by an agonist-engaged TCR upon antagonist
recognition by the other. Taken as a whole, these data
show that competition for TCR binding cannot be the
sole mechanism involved in antagonist function and fur-
ther reveal that antagonists can inhibit responses by a
TCR responding to agonist ligands of entirely distinct
specificities.
TCR Proximal Tyrosine Phosphorylation Induced
in a Dual TCR Clone after Stimulation of D10
or MBP TCR
The pattern of phosphorylation of TCR z and e chains
and the extent of phosphorylation and activation of ZAP-
70 kinase have been established as reliable indicators
of the quality of TCR interaction with peptide ligand
presented by MHC molecules (Sloan-Lancaster et al.,
1994; Madrenas et al., 1995; Reis e Sousa et al., 1996;
La Face et al., 1997; Hemmer et al., 1998). To determine
if the present characterization of peptide ligands by
functional studies was consistent with these biochemi-
cal phenotypes, we examined the signaling responses
of the D10 and the MBP TCR receptors after interaction
with individual peptides presented by either I-Ak- or I-Au-
expressing fibroblasts (Figure 5). In agreement with the
Figure 3. Dose-Dependent Peptide Antagonism of the D10/MBP interpretation of the functional studies, the 5-3 dual TCR
5-3 Clone
clone recognized K4M, K4A, and CA134-146 presented
(B10.BR/B10.PL)F1 splenocytes were prepulsed with CA134-146 (10
by the relevant MHC class II molecule as agonists and
mg/ml) (A and B) or K4A (40 mg/ml) (C and D) for 2 hr at 378C before
induced generation of both p21z and p23 (Figure 5). Thecoculture with the D10/MBP 5-3 clone in the presence or absence
ratio of p23/p21z and the intensity of phospho-e andof W7M ([A] and [C], closed circle), E8A ([A] and [C], open circle),
Q3AK4M ([B] and [D], open circle), or HEL30-53 ([B] and [D], closed phospho-ZAP-70 elicited in response to CA134-146
circle) offered at 1.2 to 100 mM. The prepulse level is proliferation were repeatedly lower when compared to the agonists
in response to CA134-146 or K4A prepulsed APC in the absence of formed by K4M and K4A, suggesting that the former
added peptide. Proliferation was measured as for Figure 1. peptide creates a low activity agonist ligand for the D10
TCR (Figure 5). Compared to other TCR:ligands pairs,
even the K4M agonist shows a less than optimal p23/
inhibition of the response of the D10/MBP 5-3 clone p21 ratio and production of a low level of phosphorylated
through the MBP TCR upon exposure to the Q3AK4M ZAP-70 (Figure 5; data not shown). The signaling pat-
antagonist at the same time as stimulation through the terns seen with these stimulatory ligands were neverthe-
D10 TCR with the CA134-146 agonist. The reciprocal less clearly different from those induced by the peptides
experiment involving engagement of the D10 TCR with forming inhibitory ligands (antagonists). The latter trig-
the E8A antagonist together with K4A agonist recogni- gered only partial phosphorylation of the z chain, gener-
tion through the MBP TCR showed similar cross-inhibi- ating almost exclusively p21-phospho-z (Figure 5). The
tion (Figure 3C). intensity of p21z correlated with each antagonist li-
To test whether the agonist and antagonist ligands gand's potency in inhibiting agonist signaling (Figure 1),
must be presented together on the same APC or could with the most effective functional antagonists Q3AK4M,
be presented on separate APC, we performed antago- K4MR5L, and E8A eliciting the strongest partial phos-
nist assays using I-Ak, I-Au, I-Akxu, or a 1:1 mixture of phorylation of z. Q3AK4A and K4AR5L, relatively less
I-Ak 1 I-Au APC. Inhibition of a D10-TCR clone with E8A potent antagonists, induced only moderate p21z signals
was achieved when CA134-146 prepulsed APC ex- (Figure 5). Q3A and R5L induced z phosphorlation that
pressed I-Ak (Figure 4A) or I-Akxu (Figure 4B) or when was barely detectable over the signal present in control
prepulsed I-Ak APC were mixed with I-Au APC (Figure cells (Figure 5A), in accord with their very limited capac-
4C). Using the D10/MBP 5-3 clone, E8A, but not ity to antagonize responses to agonist (Figure 1).
Q3AK4M, inhibited proliferation to CA134-146 pre-
pulsed I-Ak APC (Figure 4D). When I-Akxu APC were pre- Early Transinhibition of Protein Tyrosine Kinase
pulsed with CA134-146, as in Figure 3, inhibition was Activity in TCR Stimulated with Agonist in the
observed with both the E8A and Q3AK4M peptides (Fig- Presence of Signals Generated by Antagonist
ure 4E). In the case of I-Akxu APC, both the agonist Having demonstrated that the agonist and antagonist
CA134-146 and the antagonist Q3AK4M have the capac- ligands characterized here for the D10 and MBP TCR
ity to be presented on the same APC (Figures 4B and evoke intracellular signaling patterns predicted by previ-
4E). When I-Ak APC prepulsed with the agonist CA134- ous studies, we asked whether these patterns were al-
tered in quality and/or amount under conditions in which146 peptide were mixed with I-Au APC, E8A but not
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Figure 4. Dose-Dependent Peptide Antago-
nism of the D10.2.2 and the D10/MBP 5-3
Clone
B10.BR (I-Ak) and (B10.BR/B10.PL)F1 (I-Akxu)
splenocytes were prepulsed with CA134-146
for 2 hr at 378C before coculture with the
D10.2.2 and D10/MBP 5-3 clones in the pres-
ence or absence of W7M (closed circle), E8A
(open circle), HEL30-53 (closed square), or
Q3AK4M (open square) used at 1.2 to 100
mM. B10.BR splenocytes were prepulsed with
2.5 mg/ml (A, C, and D) or 5 mg/ml (F) CA134-
146, and the (B10.BR/B10.PL)F1 splenocytes
were prepulsed with 10 mg/ml (B and E)
CA134-146. B10.BR (1 3 105) (A, C, D, and
F) or 2 3 105 (B10.BR/B10.PL)F1 (B and E)
splenocytes were cocultured with 2 3 104
clone cells. In (C) and (F), 1 3 105 B10.PL (I-Au)
splenocytes were used. The prepulse level is
proliferation in response to CA134-146 pre-
pulsed APC in the absence of added peptide.
Proliferation was measured as for Figure 1.
functional transinhibition is seen, that is, when an antag- in the total level of TCR-associated Lck (Figure 6). The
Lck associated with the D10 receptor in the resting stateonist ligand engaging one TCR inhibits the response to
agonist seen by the second TCR of the 5-3 clone. D10 was primarily in the p56 mobility state, whereas after
agonist exposure and during the peak of increase inTCR complexes isolated from cells stimulated with ago-
nist for this receptor in the absence or in the presence kinase activity, both the p56 and p59 mobility isoforms
were observed (Figure 6). p59 Lck is a serine phosphory-of antagonist for the MBP TCR were analyzed for associ-
ated protein kinase activity and for the presence of Lck. lated form of Lck, presumably generated by the action
of activated MAP kinase (Winkler et al., 1993). ThisThis is a key tyrosine kinase involved in phosphorylation
of receptor-associated proteins and downstream signal change in Lck mobility thus indicates effective down-
stream signaling triggered by interaction of the D10 TCRpropagation in T cells (Straus and Weiss, 1992). In cells
stimulated with CA134-146 only, increased kinase activ- with agonist ligand.
In contrast, kinase activity in the D10 TCR decreasedity was observed in the TCR complex along with a rise
Figure 6. Simultaneous Presentation of Agonist and Antagonist In-Figure 5. Early Signaling Induced in the Dual TCR T Cell Clone by
Agonist and Antagonist Peptides hibits Tyrosine Kinase Activity in Agonist-Stimulated TCR in the
Absence of Recruited LckT cells were stimulated with the indicated peptides using pulsed
I-Au (lanes 1±9) or I-Ak (lanes 10±12) L cells for 5 min. Tyrosine T cells were stimulated for indicated periods of time using peptide-
pulsed splenocytes from (B10.BR/B10.PL)F1 mice. Agonist CA134-phosphorylation of ZAP-70 and the z chain in anti-ZAP-70 immuno-
precipitated complexes was visualized by anti-phosphotyrosine im- 146 was used at 10 mg/ml and antagonist Q3AK4M at 100 mg/ml.
D10 TCR were isolated from stimulated cells and then analyzed formunoblotting. The equal level of ZAP-70 in all samples is shown in
the first panel. Different exposures of the ZAP-70 and the phosphor- kinase activity (upper row), for the presence of Lck (middle row),
and for z (lower row). All the data in Figure 6 are from the sameylated z chain are shown to allow comparison of the patterns seen
under strong and weak stimulatory conditions. experiment, blotted on the same membrane.
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within the first 5 min in T cells stimulated with CA134-
146 in the presence of the Q3AK4M antagonist for the
MBP TCR, despite the fact that additional Lck was still
recruited into the D10 TCR under these conditions (Fig-
ure 6). In contrast to what was observed using agonist
alone, this recruited Lck consisted almost exclusively
of the 56 kDa form, indicating limited downstream sig-
naling through the MAPK pathway. Thus, the functional
inhibition mediated in trans using antagonists with the
dual TCR 5-3 clone was reflected in a very early change
in the signaling properties of the agonist-engaged TCR,
a change that involved interference with the enzymatic
activity of recruited receptor-associated tyrosine kinase.
Infectious Antagonism: Antagonist-Engaged
Receptors Induce SHP-1 Association with
Bystander Unengaged Receptors
TCR recognition of peptide antagonists interfered with Figure 7. SHP-1 Is Recruited into Nonengaged Bystander TCR
the signaling competency of distinct receptors engaged T cells were stimulated with the indicated peptides using pulsed
by agonist (Figure 6). This effect could not be explained I-Au L cells. Tyrosine phosphorylation of the z chain in immunopre-
by competition between TCR for the key initial protein cipitated total (A) and specific D10 TCR complexes (B) was visual-
ized by anti-phosphotyrosine immunoblotting. SHP-1 in D10 TCRtyrosine kinase Lck, because the total level of Lck inte-
was detected by SHP-1 immunoblotting (B). Transient exposure tograted into agonist-engaging TCR is comparable in cells
antagonist for the MBP TCR interferes with the subsequent re-exposed to agonist either in the presence or in the ab-
sponse of the unengaged D10 TCR to agonist. T cells preexposed
sence of antagonist for the second TCR. These data to I-Au L cells in the presence or absence of antagonist Q3AK4M
were also inconsistent with simple competition models peptide were stimulated for 5 min with I-Ak L cells pulsed with 100
for antagonist function, given the distinct specificities mg/ml CA134-146 peptide. Tyrosine phosphorylation and ZAP-70
protein in anti-ZAP-70 immunoprecipitated complexes were visual-of the two TCR involved and the gain in Lck. They
ized by anti-phosphotyrosine and anti-ZAP-70 immunoblotting, re-seemed best explained by a model involving antagonist-
spectively.mediated induction or recruitment into the TCR com-
plexes of a negative regulator of tyrosine kinases, which
in the case of the dual TCR clone as studied here would
recruited into the D10 TCR after T cell stimulation withnecessarily involve the spread of such a negative signal
an agonist for the MBP TCR but only after 20 min offrom the antagonist-engaged TCR to those recognizing
stimulation. This result is again consistent with our pre-agonist. We have recently found that antagonist engage-
vious observation of the delayed kinetics of SHP-1 re-ment induces the rapid recruitment of one such inhibi-
cruitment into TCR of agonist-stimulated cells (I. S. ettory molecule to the TCR, namely the hematopoietic
al., submitted).tyrosine phosphatase SHP-1, accompanied by a loss
of Lck kinase activity in the affected TCR (I. S. et al.,
submitted). This previous study of SHP-1 recruitment Infectious Spread of SHP-1 upon Antagonist
Recognition Leads to Desensitizationinvolved cells with a single TCR specificity, however,
and therefore could not distinguish between SHP-1 inhi- of Previously Unengaged TCR
A prediction of the TCR competition model for antago-bition of only those TCR directly engaged by antagonist
or a potential transinhibitory effect of SHP-1 on by- nist function (Daniels et al., 1999; Stotz et al., 1999) is
that separating exposure of the T cell to antagonist andstander TCR. The data on transinhibition of Lck activity
in the dual TCR clone (Figure 7) suggested the later agonist in time should prevent inhibition. In a human
T cell model, we have recently found that sequentialscenario as a more likely alternative. To look for ªSHP-1
spreadingº in the dual TCR clone, we stimulated the T exposure to antagonist and then agonist alone still led
to response inhibition that correlated with the presencecells with L cells expressing I-Au presenting either ago-
nist (K4M) or antagonist (Q3AK4M) peptides for the MBP of SHP-1 in the antagonist-prestimulated TCR (I. S. et
al., submitted). Based on these data, we expected thatTCR and analyzed total z phosphorylation (Figure 7A)
and also the level of SHP-1 in the nonengaged D10 TCR the infectious spread of SHP-1 to unengaged D10 TCR in
cells preexposed to antagonist for the MBP TCR should(Figure 7B). A sustained rise in SHP-1 associated with
the D10 TCR began within the first minute of exposure reduce the subsequent signaling performance of the
D10 TCR. To examine this possibility, the APC present-of the T cells to APC presenting antagonist for the MBP
TCR. The z chain in the D10 TCR complex was not ing Q3AK4M antagonist were separated from 5-3 cells
after a first incubation that allowed extensive T cell con-phosphorylated, consistent with absence of the I-Ak-
presenting element in the system. This lack of tyrosine tact with only antagonist-bearing APC over a prolonged
time, to induce a sufficient degree of SHP-1 spreading.phosphorylated proteins in the anti-D10 immunoprecipi-
tate also excludes the possibility that SHP-1 is part of The recovered T cells were then exposed to APC pre-
senting agonist for the D10 TCR. The phosphorylationMBP TCR and simply is coprecipitated with the D10
TCR, as such coprecipitation would result in the detect- elicited in antagonist-experienced cells was diminished
compared to that of control cells (Figure 7C). This resultable presence of phospho-z (Figure 7A). SHP-1 was also
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supports the view that inhibition by antagonists can be in TCR complexes triggered by agonist in the absence
of antagonist (I. S. and R. N. G., unpublished data; Figuremediated by an active intracellular process distinct from
6). In cells exposed to both CA agonist and MBP antago-receptor competition. The binding of SHP-1 to by-
nist, the reduction in p59 Lck in TCR binding to agoniststander TCR provides at least one explanation for, and
was correlated with a decrease in total Lck kinase activ-is a mechanism consistent with, the molecular pheno-
ity associated with the D10 TCR (Figure 6). Antagonisttype of the agonist-engaged TCR in cells also exposed
exposure did not, however, inhibit the recruitment ofto antagonist, namely accumulation of Lck in the TCR
Lck into the D10 TCR complex, as shown by the increasecomplex in the absence of kinase function.
in the p56 form and by the equal levels of total Lck after
10 min in the presence or absence of antagonist (FigureDiscussion
6). Thus, an antagonist does not change the kinetics of
Lck recruitment, an early event in TCR signaling, butIn this paper, we have described and studied the TCR
changes the nature of the signaling that follows by pre-signaling properties of a novel TCR clone derived from
venting or terminating Lck function.an F1 mouse expressing two well-characterized TCR.
The observed loss of Lck kinase activity can be ac-These receptors are specific for distinct agonist pep-
counted for by the recruitment of SHP-1 tyrosine phos-tides bound to different alleles of the MHC class II A
phatase to the TCR complex. SHP-1 is tyrosine phos-locus molecule. Variants of the antigenic peptides for
phorylated by Lck at a C-terminal site that is a consensuseach TCR were produced and characterized for their
sequence for binding to the SH2 domain of Lck (Lorenzfunctional activity as TCR antagonists, as well as for
et al., 1994). Thus, Lck activation by antagonists (whichtheir generation of the previously characterized altered
explains the formation of p21z) would lead to a rise inpattern of proximal TCR-associated signaling (genera-
the intracellular levels of such phosphorylated SHP-1,tion of p21 phospho-z and recruitment but not phos-
enhancing binding to Lck associated with both the an-phorylation of ZAP-70). The antagonist ligands thus
tagonist-engaged receptors and other TCR, as we ob-identified were then used with the dual TCR clone to
serve. SHP-1 has been associated with the regulationtest whether antagonist engagement by one TCR would
of TCR signaling in several prior studies. Overexpressioninhibit responses stimulated by agonist recognition in-
of a dominant-negative form of SHP-1 enhances thevolving the other TCR. This is a critical test of several
sensitivity of the response of a T cell hybridoma or T cellsmodels proposed for the mechanistic basis of antago-
in transgenic mice expressing this mutant phosphatasenist function, especially competition for receptor occu-
(Plas et al., 1996, 1999), and a molecular defect in SHP-1pancy (De Magistris et al., 1992, Stotz et al., 1999, Dan-
in cells of motheaten mice results in prolonged thymo-iels et al., 1999).
cyte proliferative responses associated with constitutiveCross-inhibition of responses induced by an agonist
tyrosine phosphorylation of TCR components, sug-for one TCR in the presence of antagonist for the other
gesting the absence of negative regulator of TCR signal-was observed in both directions when the two types of
ing (Pani et al., 1996). Following stimulation with an ago-ligands were present on the same APC. Such transinhibi-
nist, SHP-1 is not visibly recruited to the TCR complex
tion was associated with accumulation of a kinase-inac-
for 5±10 min, after which time the signaling pattern of
tive p56 form of Lck in the TCR recognizing agonist. In
the agonist-engaged TCR changes to one more charac-
dual TCR cells exposed to antagonist alone, even TCR
teristic of partial agonist/antagonist recognition (Figure
not recognizing added ligand and lacking detectable 7; I. S. et al., submitted). Antagonist ligands induce much
phosphorylation could be shown to be associated with more rapid SHP-1 recruitment into the TCR complex,
the phosphatase SHP-1. Finally, transient exposure to with readily detectable levels seen within the first minute
antagonist for one TCR, followed sequentially by expo- of stimulation (Figure 7; data not shown). The promotion
sure to only agonist for the other receptor, revealed of SHP-1 binding to TCR induced by antagonist recogni-
reduced phosphorylation responses consistent with the tion is ªinfectious,º spreading to surrounding agonist-
expected effect of preassociated SHP-1 on signaling by engaged TCR or even TCR not exposed to any cognate
these agonist-engaged TCR. These observations sug- peptide or MHC molecule, and hence presumably unen-
gest that antagonism is mediated, at least in part, by gaged by ligand. The interference with signaling re-
an active process distinct from either competitive inhibi- sulting from SHP-1 recruitment arises from limiting ki-
tion of individual or serial agonist recognition events (De nase activity and not from loss of kinase association
Magistris et al., 1992; Viola et al., 1997; Stotz et al., 1999) with the TCR, thus differing from the sequestration of
or from sequestration of the initiating tyrosine kinase Lyn kinase concluded to underlie low-affinity ligand an-
(Torigoe et al., 1998). This negative regulatory process tagonism of high-affinity ligand activation of IgE recep-
accompanying antagonist recognition can lead to inacti- tors (Torigoe et al., 1998). This previous study of IgE
vation of Lck in receptors engaging agonist, contributing receptor activation did not directly examine the level of
to incomplete phosphorylation of TCR-associated pro- Lyn in the antagonized receptors, however, leaving open
teins, interference with effective signal transduction, the possibility that an inhibition of kinase function rather
and reduced cellular responses. than sequestration was involved, which would be con-
In the presence of antagonist, there was a reduction sistent with the Lck data described here.
in the appearance of the p59 form of Lck in association Stotz et al. (1999) and Daniels et al. (1999) failed to see
with the TCR complexes involved in agonist recognition. cross-antagonism using either a dual TCR hybridoma or
This isoform of Lck is generated by serine phosphoryla- short-term line with two TCR. Although these two prior
tion at residue 59 mediated by MAPK (Winkler et al., studies used CD81 T cells with class I ligands, we do
not think that this accounts for the different findings, as1993) and is seen as a predominant form of the enzyme
Immunity
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Experimental Procedureswe have seen similar accelerated recruitment of SHP-1
to the TCR using antagonists with human CD81 T cells
Mice(Stefanova et al., unpublished data). Thus, the divergent
B10.PL (I-Au) and B10.BR (I-Ak) mice were purchased from the Jack-
outcomes may indicate that multiple mechanisms, in- son Laboratory. The MBP TCR transgenic (tg) mouse and the D10
cluding both active negative regulation and competition TCR tg mouse were generated as previously described (Hardardottir
et al., 1995; Dittel et al., 1997, respectively). (B10.BR/B10.PL)F1 micefor TCR engagement, can contribute to antagonist func-
and D10/MBP double tg mice were generated by intercrossing andtion. However, SHP-1 infection of TCR other than those
maintained in our colony at Yale University.directly engaged by antagonist is likely to be less exten-
sive than SHP-1 recruitment to the engaged TCR them-
Peptides and Antibodiesselves. In this case, antagonist recognition followed by
The MBP Ac1-11 and the MBP analog peptides K4A, K4M, Q3A,
dissociation and then agonist binding to the same TCR Q3AK4A, Q3AK4M, R5L, K4AR5L, and K4MR5L and the CA134-146
pool would result in visible inhibition due to the high and the CA134-146 analog peptides W7M and E8A (Dittel et al.,
1997) were synthesized at Yale University. All analog peptides arelevel of SHP-1 preloading. In contrast, agonist binding
named using the single letter code for the residue found in the nativeto a distinct set of receptors might result in a much
protein at the position given with a number, followed by the singlemore modest, perhaps unmeasurable, effect if infectious
letter code for the residue to which it was changed. Thus, a peptide
spread of SHP-1 among receptors of distinct specificity with the lysine (K) at position 4 of Ac1-11 substituted with an alanine
were more limited. This could lead to a failure to see (A) is called K4A. The following antibodies were used in these experi-
ments: 3D3 (clonotypic mAb specific for the D10 TCR) (Kaye et al.,transinhibition in a two TCR system, especially using
1983); 19G (clonotypic mAb specific for the MBP TCR) (Baron et al.,optimal agonists, while still allowing antagonists engag-
1993); goat anti-mouse-FITC (Fc specific) (Sigma Chemical); strep-ing the same TCR pool as the agonist to cause inhibition
tavidin-PE (Caltag); 2.4-G2 (anti-Fc receptor) (American Type Cul-
through SHP-1 recruitment. The description here of a ture Collection, Rockville, MD); rabbit antiserum to ZAP-70, z Lck
molecular phenotype for TCR affected by SHP-1 nega- (Burkhardt et al., 1994), and SHP-1 (Upstate Biotechnology); 4G10
tive feedback provides a method to directly investigate (anti-phosphotyrosine [Upstate Biotechnology]; H57 (anti-mouse
TCRb [PharMingen]); and peroxidase-linked goat antibodies tothis possibility.
mouse and rabbit IgG (Bio-Rad Laboratories).T cell activation has recently been shown to be hierar-
chical in nature, both on a kinetic and quantitative basis.
T CellsThus, different responses require a shorter or longer
The D10 TCR Th2.3 and D10.2.2 clones were generated from a D10
duration or a greater or lesser amount of effective TCR tg mouse, the MBP.31 clone was generated from a MBP tg mouse,
signaling to reach the threshold necessary for their elic- and the D10/MBP 5-3 clone was generated from a D10/MBP dual
itation (Viola and Lanzavecchia, 1996; Itoh and Germain, TCR tg mouse as previously described (Dittel et al., 1997). The clone
19 clone has been previously described (Baron et al., 1993).1997; Iezzi et al., 1998). Analysis in parallel of multiple
variant ligands for the same TCR has demonstrated that
Immunofluorescencea higher density of partial agonist ligand is needed to
Immunofluorescence staining using anti-D10 TCR (3D3-biotin de-reach the same total generation of effective intracellular
tected with SA-PE) and anti-MBP TCR (19G detected with anti-
signals as agonist but that when such similar total signal- mouse FITC) was carried out as previously described (Dittel et al.,
ing occurs the responses induced by the two distinct 1997) on clones generated from the D10 tg, MBP tg, and the D10/
ligands for many (though not all) measurable parameters MBP tg mice.
are the same (Hemmer et al., 1998). Thus, T cells for the
most part have their activity directed by the integrated Proliferation and Antagonist Assays
T cell proliferation and antagonist assays were carried out as pre-level of effective signaling, rather than by the presence
viously described (Dittel et al., 1997). In brief, 1±2 3 104 T cells wereof unique signals induced by partial agonists/antago-
incubated with 1±2 3 105 splenocytes from B10.BR, B10.PL, or
nists. In the context of the results described here, this (B10.BR/B10.PL)F1 mice in the presence of peptides. For antagonist
suggests that TCR antagonists mediate their inhibitory assays, the splenocytes were prepulsed with agonist CA134-146,
effects by limiting effective signaling in either amount K4A, or K4M peptides for 2 hr at 378C in serum free medium. MAb
inhibition of proliferation was performed using 1 3 104 D10/MBP 5-and/or duration. Our previous studies have shown that
3 cells cocultured with 1 3 105 splenocytes from B10.PL or B10.BRlike antagonists, agonists induce SHP-1 association
mice in the presence of 0.5 mg/ml Ac1-11 or 0.05 mg/ml CA134-with the TCR and interfere with Lck function, but they
146, respectively. MAb 2.4-G2 was added (10 mg/ml) to block Fc
do so with a substantial time delay. Antagonists alter receptors on the APC. Either serial 1:10 dilutions of purified 3D3
the rate of such TCR desensitization, reducing the time were added from 0.001 to 10 mg/ml, or serial 1:2 dilutions of 19G
ascites from 1:150 to 1:2400 were added. Cultures were pulsed afterover which complete signals are delivered and also lim-
48 hr with 0.5±1 mCi of [3H]TdR and harvested after 15±18 hr.iting the absolute amount of effective signal at any time
to a level below the threshold for certain responses.
Stimulation and Processing of T Cells for AnalysisThis should result in more effective inhibition of those
of Signaling Moleculesoutcomes requiring the most/longest duration of TCR
T cells (5 3 106) were added to peptide-pulsed L cells stably trans-
signaling, and this is seen in experiments analyzing an- fected with cDNA expression construct encoding I-Ak or I-Au (2 3
tagonist inhibition of more than a single response pa- 106) or to splenocytes from (B10.BR/B10.PL)F1 mice (25 3 106). After
centrifugation at 1000 rpm for 10 s, the cells were incubated at 378Crameter (Hemmer et al., 1998). Viewed in this manner,
for the indicated period of time. After incubation, cells were washedTCR antagonism is primarily a disturbance in the regula-
once with PBS and placed in lysis buffer containing 1% NP-40 (ZAP-tion of TCR desensitization that typically serves to shut
70 immunoprecipitation) or 1% Brij96 (TCR immunoprecipitation),
down an effective signaling response after sufficient 10 mM Tris-HCl (pH 7.2), 140 mM NaCl, 2 mM EDTA, 5 mM iodoacet-
time has passed for the proper gene activation events amide, 1 mM Na3VO4 (Sigma), and complete protease inhibitor cock-
tail (Boehringer Mannheim). After removal of nuclear debris byto transpire.
Cross-Antagonism between T Cell Receptors
297
centrifugation, the resultant supernatants were subjected to immu- (1999). Cutting edge: a test of the dominant negative signal model
for TCR antagonism. J. Immunol. 162, 3761±3764.noprecipitation and analyzed by immunoblotting or by an in vitro
kinase assay. De Magistris, M.T., Alexander, J., Coggeshall, M., Altman, A., Gaeta,
For sequential stimulation, the I-Au-expressing L cells were first F.C.A., Grey, H.M., and Sette, A. (1992). Antigen analog-major histo-
incubated with magnetic beads covered with goat anti-mouse Ig compatibility complexes act as antagonists of the T cell receptor
(Dynal, Oslo, Norway) for 8 hr at 378C. Cells containing beads were Cell 68, 625±634.
recovered by magnet, washed, and preincubated with antagonist Dittel, B.N., Sant'Angelo, D.B., and Janeway, C.A., Jr. (1997). Peptide
peptide (Q3AK4M; 300 mg/ml) for 6 hr at 378C. After this period, T antagonists inhibit proliferation and the production of IL-4 and/or
cells were added and incubated in the continued presence of IFNg in T helper 1, T helper 2, and T helper 0 clones bearing the
Q3AK4M peptide for 6 hr. Control T cells were exposed for the same TCR. J. Immunol. 158, 4065±4073.
same time period to I-Au cells containing magnetic beads but in Fairchild, P.J., Wildgoose, R., Atherton, E., Webb, S., and Wraith,
the absence of antagonist. Bead-containing cells were removed by D.C. (1993). An autoantigenic T cell epitope forms unstable com-
magnet, and the T cells were washed. For signaling studies, control plexes with class II MHC: a novel route for escape from tolerance
and antagonist preexposed T cells (1 3 106) were added to agonist induction. Int. Immunol. 5, 1151±1158.
(CA136-147, 100 mg/ml)-pulsed I-Ak presenting cells (1 3 106), spun
Fugger, L., Liang, J., Gautam, A., Rothbard, J.B., and McDevitt, H.O.at 1000 rpm for 10 s, and incubated at 378C for 5 min.
(1996). Quantitative analysis of peptides from myelin basic protein
binding to the MHC class II protein, I-Au, which confers susceptibility
Immunoprecipitation, Protein Kinase Assay,
to experimental allergic encephalomyelitis. Mol. Med. 2, 181±188.
and Immunoblotting
Hardardottir, F., Baron, J.L., and Janeway, C.A., Jr. (1995). T cellsZAP-70 and TCR were immunoprecipitated by incubation of lysates
with two functional antigen-specific receptors. Proc. Natl. Acad. Sci.with optimized amounts of polyclonal antisera or mAb on ice for 4
USA 92, 354±358.hr. Immunocomplex protein kinase assays, SDS-PAGE, and immu-
Hemmer, B., Stefanova, I., Vergelli, M., Germain, R.N., and Martin,noblotting were performed as previously described (Stefanova et
R. (1998). Relationships among T cell receptor ligand potency,al., 1993). For the protein kinase assay, immunoprecipitates were
thresholds for effector function elicitation, and the quality of earlyincubated with 50 ml of 25 mM Hepes (pH 7.2), containing 3 mM
signaling events in human T cells. J. Immunol. 160, 5807±5814.MnCl2, Brij96 (0.1%), and 1 mCi of [g-32P]ATP (NEN). After incubation
Iezzi, G., Karjalainen, K., and Lanzavecchia, A. (1998). The durationfor 10 min at 258C, proteins were eluted in sample buffer and sub-
of antigenic stimulation determines the fate of naive and effector Tjected to SDS-PAGE and autoradiography. Quantitative data were
cells. Immunity 8, 89±95.obtained from film exposures using a Molecular Dynamics Laser
Densitometer. Itoh, Y., and Germain, R.N. (1997). Single cell analysis reveals regu-
lated hierarchical T cell antigen receptor signaling thresholds and
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